Technical Articles

In the field of metabolic disease treatment, the Activin Type II Receptor (ActRII) is emerging as a focal point of competition among global pharmaceutical companies. As a core member of the TGF-β superfamily, ActRII regulates the metabolic balance between fat and muscle, offering a novel therapeutic paradigm for metabolic disorders such as obesity and sarcopenia. With major players like Eli Lilly, Merck, and China's innovative biopharma companies such as Laekna Therapeutics making significant investments, the ActRII target is propelling metabolic drug research into a new era of "simultaneous fat reduction and muscle enhancement."